{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:46:30Z","timestamp":1791071190225,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"S3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of life. There is no robust evidence that ESAs, when used as indicated, have a negative effect on survival in patients with solid tumors. When used outside the indications recommended, the rise in Hb level that results may reduce tumor blood flow and tissue oxygenation because of a raised viscosity within the abnormal tumor microvasculature. In the current situation, it remains important to use ESAs within the approved indications and according to treatment guidelines such as those developed by the European Organization for Research and Treatment of Cancer.<\/jats:p>","DOI":"10.1634\/theoncologist.13-s3-21","type":"journal-article","created":{"date-parts":[[2008,5,5]],"date-time":"2008-05-05T18:52:57Z","timestamp":1210013577000},"page":"21-26","source":"Crossref","is-referenced-by-count":324,"title":["Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis"],"prefix":"10.1093","volume":"13","author":[{"given":"Peter","family":"Vaupel","sequence":"first","affiliation":[{"name":"Institute of Physiology and Pathophysiology, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2021122206412598400_R1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"2021122206412598400_R2","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122206412598400_R3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0360-3016(99)00384-3","article-title":"Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas","volume":"46","author":"Becker","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122206412598400_R4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00066-006-1543-7","article-title":"Impact of hemoglobin levels on tumor oxygenation: The higher, the better?","volume":"182","author":"Vaupel","year":"2006","journal-title":"Strahlenther Onkol"},{"key":"2021122206412598400_R5","first-page":"7634","article-title":"Oxygenation gain factor: A novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers","volume":"63","author":"Vaupel","year":"2003","journal-title":"Cancer Res"},{"key":"2021122206412598400_R6","first-page":"4509","article-title":"Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix","volume":"56","author":"H\u00f6ckel","year":"1996","journal-title":"Cancer Res"},{"key":"2021122206412598400_R7","first-page":"47","article-title":"Effects of anaemia and hypoxia on tumor biology","volume-title":"Anaemia in Cancer. European School of Oncology Scientific Updates","author":"Vaupel","year":"2005","edition":"Second Edition"},{"key":"2021122206412598400_R8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: Significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"2021122206412598400_R9","article-title":"Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer","author":"Yamamoto","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"2021122206412598400_R10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10715760701361531","article-title":"Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells","volume":"41","author":"Alqawi","year":"2007","journal-title":"Free Radic Res"},{"key":"2021122206412598400_R11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4020-5133-3_16","article-title":"Effect of hypoxia on the tumor phenotype: The neuroblastoma and breast cancer models","volume":"587","author":"Holmquist","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"2021122206412598400_R12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.semcdb.2005.03.007","article-title":"Hypoxia-induced dedifferentiation of tumor cells\u2013a mechanism behind heterogeneity and aggressiveness of solid tumors","volume":"16","author":"Axelson","year":"2005","journal-title":"Semin Cell Dev Biol"},{"key":"2021122206412598400_R13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/er.2002-0008","article-title":"Angiogenesis in endocrine tumors","volume":"24","author":"Turner","year":"2003","journal-title":"Endocr Rev"},{"issue":"suppl 5","key":"2021122206412598400_R14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/theoncologist.9-90005-10","article-title":"The role of hypoxia-induced factors in tumor progression","volume":"9","author":"Vaupel","year":"2004","journal-title":"The Oncologist"},{"key":"2021122206412598400_R15","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res"},{"key":"2021122206412598400_R16","first-page":"4010","article-title":"Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth","volume":"60","author":"Ryan","year":"2000","journal-title":"Cancer Res"},{"key":"2021122206412598400_R17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2021122206412598400_R18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"2021122206412598400_R19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1053-4296(96)80035-X","article-title":"Hypoxic stress proteins: Survival of the fittest","volume":"6","author":"Giaccia","year":"1996","journal-title":"Semin Radiat Oncol"},{"key":"2021122206412598400_R20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1172\/JCI13374","article-title":"Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance","volume":"108","author":"Semenza","year":"2001","journal-title":"J Clin Invest"},{"key":"2021122206412598400_R21","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0006-291X(91)91276-I","article-title":"Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells","volume":"181","author":"Pepper","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122206412598400_R22","first-page":"137","article-title":"Proteolytic balance and capillary morphogenesis in vitro","volume":"61","author":"Pepper","year":"1992","journal-title":"EXS"},{"key":"2021122206412598400_R23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.gde.2004.12.005","article-title":"Cellular abnormalities of blood vessels as targets in cancer","volume":"15","author":"Baluk","year":"2005","journal-title":"Curr Opin Genet Dev"},{"key":"2021122206412598400_R24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/0470035439.ch2","article-title":"Abnormal microvasculature and defective microcirculatory function in solid tumors","volume-title":"Vascular-targeted Therapies in Oncology","author":"Vaupel","year":"2006"},{"key":"2021122206412598400_R25","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","article-title":"Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1","volume":"16","author":"Forsythe","year":"1996","journal-title":"Mol Cell Biol"},{"key":"2021122206412598400_R26","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"key":"2021122206412598400_R27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10409230091169186","article-title":"Hypoxia, clonal selection, and the role of HIF-1 in tumor progression","volume":"35","author":"Semenza","year":"2000","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2021122206412598400_R28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1083\/jcb.200208117","article-title":"Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins","volume":"160","author":"Czekay","year":"2003","journal-title":"J Cell Biol"},{"key":"2021122206412598400_R29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tracli.2004.11.005","article-title":"Hypoxia and anemia: Effects on tumor biology and treatment resistance","volume":"12","author":"Vaupel","year":"2005","journal-title":"Transfus Clin Biol"},{"key":"2021122206412598400_R30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/ars.2007.1628","article-title":"Detection and characterization of tumor hypoxia using pO2 histography","volume":"9","author":"Vaupel","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"2021122206412598400_R31","first-page":"216","article-title":"Effect of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia","volume":"28","author":"Vaupel","year":"2005","journal-title":"Onkologie"},{"issue":"suppl 1","key":"2021122206412598400_R32","first-page":"S47","article-title":"Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: What have we learned?","volume":"15","author":"\u00d6sterborg","year":"1998","journal-title":"Med Oncol"},{"key":"2021122206412598400_R33","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122206412598400_R34","first-page":"8903","article-title":"Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors","volume":"61","author":"Cairns","year":"2001","journal-title":"Cancer Res"},{"key":"2021122206412598400_R35","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1158\/0008-5472.CAN-03-3196","article-title":"Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma","volume":"64","author":"Cairns","year":"2004","journal-title":"Cancer Res"},{"key":"2021122206412598400_R36","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1158\/1078-0432.CCR-06-1967","article-title":"Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis","volume":"13","author":"Rofstad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122206412598400_R37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00066-008-1841-3","article-title":"Erythropoiesis-stimulating agents: Favorable safety profile when used as indicated","volume":"184","author":"Nowrousian","year":"2008","journal-title":"Strahlenther Onkol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.13-S3-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.13-S3-21","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/S3\/21\/41833272\/oncolo_13_s3_21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/S3\/21\/41833272\/oncolo_13_s3_21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T06:42:55Z","timestamp":1640155375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/S3\/21\/6397382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":37,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.13-s3-21","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,5,1]]},"published":{"date-parts":[[2008,5,1]]}}}